Kodiak Sciences (KOD) Non-Current Assets (2017 - 2026)
Kodiak Sciences (KOD) reported Non-Current Assets of $130.7 million for Q1 2026, down 15.77% on a YoY basis from $155.2 million in Q1 2025, and down 4.37% quarter-over-quarter from $136.7 million in Q4 2025.
Kodiak Sciences (KOD) Non-Current Assets (2017 - 2026) Analysis & Trends
Kodiak Sciences has reported Non-Current Assets for 10 years, with the latest figure at $130.7 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 15.77% year-over-year to $130.7 million; the trailing twelve-month figure through Mar 2026 stood at $558.6 million (down 16.12% YoY), and the FY2025 full-year result was $136.7 million, down 16.45% from the prior year.
- Non-Current Assets for Q1 2026 stood at $130.7 million, down from $136.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $209.2 million in Q1 2023, with the low at $130.7 million in Q1 2026.
- Historically, Non-Current Assets has averaged $171.3 million across 5 years, with a median of $177.0 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 66.71% — and 2025, when it declined 16.45%.
- Kodiak Sciences' Non-Current Assets stood at $180.6 million in 2022, then rose by 5.23% to $190.1 million in 2023, then decreased by 13.9% to $163.6 million in 2024, then declined by 16.45% to $136.7 million in 2025, then dropped by 4.37% to $130.7 million in 2026.
- The last three Non-Current Assets figures came in at $130.7 million (Q1 2026), $136.7 million (Q4 2025), and $142.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 39.71 Mn |
| 10 | Kodiak Sciences | 1.95 Bn | 1.95 Bn | - | 130.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130.75 Mn |
| Dec 31, 2025 | 136.72 Mn |
| Sep 30, 2025 | 142.34 Mn |
| Jun 30, 2025 | 148.81 Mn |
| Mar 31, 2025 | 155.22 Mn |
| Dec 31, 2024 | 163.64 Mn |
| Sep 30, 2024 | 170.18 Mn |
| Jun 30, 2024 | 176.95 Mn |
| Mar 31, 2024 | 183.25 Mn |
| Dec 31, 2023 | 190.06 Mn |
| Sep 30, 2023 | 196.73 Mn |
| Jun 30, 2023 | 202.70 Mn |
| Mar 31, 2023 | 209.22 Mn |
| Dec 31, 2022 | 180.62 Mn |
| Sep 30, 2022 | 179.33 Mn |
| Jun 30, 2022 | 177.54 Mn |
| Mar 31, 2022 | 168.10 Mn |
| Dec 31, 2021 | 169.41 Mn |
| Sep 30, 2021 | 152.70 Mn |
| Jun 30, 2021 | 113.27 Mn |